BioTraxx. Learn More About Our AI Platform.
Deep learning, the most advanced AI technology in recent years has shown remarkable success in many industries. Since drug discovery is such a data intensive task and a tremendous amount of data has been accumulated, we believe that adoption of AI and big data technology can transform pharmaceutical industry. BioTraxx is an integrated platform of Deep learning, big Data and the Domain knowledge.
Accurate information of drug-target interaction (DTI) is the most critical element of drug discovery. Both the efficacy and safety of a drug depend on it – the affinity to the intended target affects the efficacy and the affinity to other targets (off-targets) is the major underlying cause of side effect or toxicity.
The core of the platform is an AI-enhanced model for accurate DTI prediction which integrates deep learning, molecular docking, and molecular dynamics simulations. Our technology is of much higher accuracy compared to existing in silico drug screening methods. The platform is fast and high throughput — able to evaluate millions of DTIs within days.
Why Protein Kinases?
Protein kinases are signaling proteins that have been implicated in many types of cancers and other disease like rheumatoid arthritis.
While the human genome encodes for over 500 different protein kinases, only 20 of these targets have approved treatments. Despite this, these medicines make up almost half of the targeted cancer therapies, a testament to the untapped potential of kinase inhibitors as effective treatments.
As a patient’s disease progresses, the cancer can evolve to drug resistance to existing protein kinase inhibitors, rendering them less effective and in many cases ineffective.
There is a crucial need for next generation kinase inhibitors.
With BioTraxx, our proprietary platform, we can screen millions of compounds to identify new kinase inhibitors that can be developed into effective treatments.
Latest News.
Press Release: How Local Biotech Company Leverages its Deep Learning Platform to Identify Drugs to Treat COVID
VANCOUVER, November 3, 2020 / Pharmasilico, the AI-based drug discovery company, is pleased to announce that they have leveraged their proprietary AI platform to identify 22 candidate drugs that could…
Offering Hope For a Healthier and Happier Future
4250 WESBROOK MALL VANCOUVER, BC CANADA V6T 1WT
© Pharmasilico